Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

This clinical trial evaluates the safety and feasibility of tumor treating fields (TTF) in the treatment of spinal leptomeningeal disease in patients with breast or lung cancer that has spread from where it first started (primary site) to other places in the body (metastatic). Patients wear the portable Novo TTF-200T device that produces electric fields to target areas on the body to stop the growth of tumor cells. The information from this study will help researchers develop a better treatment for leptomeningeal metastases in the future.

Trial Details

NCT ID
NCT05746325
Phase
NA
Sponsor
Mayo Clinic
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • Digital Photography
  • Lumbar Puncture
  • Magnetic Resonance Imaging
  • Medical Device Usage and Evaluation
  • Biospecimen Collection
Locations (sample)
  • Jacksonville, Florida, United States|30.33218,-81.65565

Key Eligibility Criteria

  • Age \>= 18
  • Prior tissue diagnosis of breast cancer or lung cancer
  • Confirmed diagnosis of leptomeningeal metastases (LM) with positive cerebrospinal fluid (CSF) cytology for malignancy and meningeal enhancement (ty…
  • Radiographic evidence on MRI of leptomeningeal enhancement within the cervical, thoracic or lumbar spine on spinal MRI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →